ArticleThe Journal of molecular diagnostics : JMD2020
Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients.
Article in The Journal of molecular diagnostics : JMD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- National Coordinated Care and Translational Research Program for Uveal Melanoma Pilot: Infrastructure, Biobanking, and Challenges in Liquid Biopsy Implementation in a Latin American Country.Ocular oncology and pathology · 2026Article
- Copper isotope fractionation and copper-to-zinc ratios reveal altered metal homeostasis in prostate cancer.Scientific reports · 2026Article
- Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer.NPJ precision oncology · 2025Article
- Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states.NPJ precision oncology · 2025Article
- Caught in the Act: Tumor-Immune Interactions in Circulation of Patients with Immune Marker Positive Circulating Tumor Cells.Cancers · 2025Article
- Representation learning enables robust single cell phenotyping in whole slide liquid biopsy imaging.Scientific reports · 2025Article
- Article
- Unsupervised detection of rare events in liquid biopsy assays.NPJ precision oncology · 2025Article
- Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care.Breast cancer research : BCR · 2025Review
- Contrastive Representation Learning for Single Cell Phenotyping in Whole Slide Imaging of Enrichment-free Liquid Biopsy.bioRxiv : the preprint server for biology · 2025Article
- Selective removal of proteins and microvesicles ex vivo from blood of pancreatic cancer patients using bioengineered adsorption filters.Cancer letters · 2025Article
- Microfluidics and molecular diagnostics in renal cell carcinoma: advances, challenges, and future directions.Frontiers in oncology · 2025Review
- Article
- Circulation of rare events in the liquid biopsy for early detection of lung mass lesions.Thoracic cancer · 2024Article
- Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy.BJC reports · 2024Article
- Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.Journal for immunotherapy of cancer · 2024Article
- Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma.NPJ precision oncology · 2023Article
- Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection.EBioMedicine · 2023Article
- Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms.International journal of molecular sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
Liquid biopsy allows assessment of multiple analytes, providing temporal information with potential for improving understanding of cancer evolution and clinical management of patients. Although liquid biopsies are intensely investigated for prediction and response monitoring, preanalytic variables are of primary concern for clinical implementation, including categories of collection method and sample storage. Herein, an integrated high-density single-cell assay workflow for morphometric and genomic analysis of the liquid biopsy is used to characterize the effects of preanalytical variation and reproducibility of data from a breast cancer cohort. Following prior work quantifying performance of commonly used blood collection tubes, this study completes the analysis of four time points to assay (24, 48, 72, and 96 hours), demonstrating precision up to 48 hours after collection for assay sensitivity, highly reproducible rare cell enumeration, morphometric characterization, and high efficiency and capacity for single-cell genomic analysis. For the cell-free analysis, both freezing and use of fresh plasma produced similar quality and quantity of cell-free DNA for sequencing. The genomic analysis (copy number variation and single-nucleotide variation) described herein is broadly applicable to liquid biopsy platforms capable of isolating cell-free and cell-based DNA. Morphometric parameters and genomic signatures of individual circulating tumor cells were evaluated in relation to patient clinical response, providing preliminary evidence of clinical validity as a potential biomarker aiding clinical diagnostics or monitoring progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.